Monday, November 19, 2012
Treatments in Development
As mentioned above, refers to a growing body of evidence that the cause of MS is the result of a defect in the immune system, which lymphocytes, macrophages and cytokines play a pivotal role. Therefore, we have developed different strategies for therapeutic intervention on different parameters of the immune and inflammatory responses, or block. These strategies rely different orientations.
The development of drugs that stimulate the immune more selective to avoid potential side effects associated with generalized immune.
Development of materials. On cytokine production by promoting anti-inflammatory cytokines (IL-4, IL-5 and IL-10) at the expense of cytokine production pro-inflammatory (IL-2, IFN-gamma, alpha tumor necrosis factor) data indicate that IFN-beta clinical signs in reducing This much activity on MRI, along with a note that this will be the impact of a change in the balance between pro-inflammatory cytokines and anti-inflammatory cytokines is an important criterion for research in this area have lead.